Celera Genomics appoints Robert Booth Senior Vice President, Research & Development
Rockville, MD - July 08, 2002
Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that Robert F.G. Booth, Ph.D., has been appointed Senior Vice President of Research & Development, effective August 5, 2002. Dr. Booth will report to Kathy Ordoñez, President of Celera Genomics.
In this new position, Dr. Booth will be responsible for integrating and leading all of Celera’s therapeutic discovery and development activities. He will oversee an R&D staff of approximately 300 people, including scientists supporting the proteomics, informatics and bioinformatics projects ongoing in Rockville, as well as the small molecule therapeutics programs in South San Francisco, CA.
“Robert brings to Celera extensive drug discovery and development experience in a variety of disease areas, and a history of outstanding accomplishment,” said Ms. Ordoñez. “With his solid track record of leading successful programs to identify new therapeutic compounds and advance them into clinical trials, Robert has demonstrated sound scientific and commercial judgment. In addition, he shares Celera’s vision for creative utilization of advanced genomic, proteomic, and bioinformatic techniques to drive the discovery process.”
Dr. Booth has over 20 years of experience in the pharmaceutical industry, the past 13 with Hoffmann-La Roche. In his most recent position, Dr. Booth was Senior Vice President responsible for the Inflammatory and Viral Diseases Business Unit, as well as Central R&D at Roche Bioscience. In this role, he was responsible for creating strategies and directing research activities to generate new therapeutics. Dr. Booth was a member of the Global Research Management Team and was recently appointed the Head of the Global Biology Team. In addition, he orchestrated a number of key external therapeutic collaborations.
Previously, Dr. Booth spent three years managing research activities at Wellcome Research Laboratories, and four years at Searle Research & Development.
Under Dr. Booth’s direction, compounds have advanced through the various phases of clinical development. He oversaw research biology during the development of Saquinavir, the first HIV protease inhibitor to receive FDA approval.
About Celera Genomics and Applera Corporation
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its genomic and proteomic technology platforms to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Its Celera Discovery SystemTM online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics, a joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available on the World Wide Web at www.celera.com.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.